Aerovate Therapeutics Stock Plummets After Drug Failure
Aerovate Therapeutics' stock plummeted over 90% as their drug for pulmonary arterial hypertension, AV-101, failed in Phase 2 testing,...
pulmonary arterial hypertension
Liquidia Shares Down as FDA Continues Yutrepia Review
Liquidia's shares dropped 10% in premarket trading after the U.S. Food and Drug Administration (FDA) announced that it is...
MannKind Enters Royalty Agreement for Tyvaso DPI
MannKind Corp. has entered a royalty agreement with Sagard Healthcare, where Sagard will receive 1% of royalty sales of...
MannKind Sells 1% Royalty Interest in Tyvaso DPI Sales for Up to $200 Million
MannKind, a biopharmaceutical company, has sold a 1% royalty interest in sales of the lung-disease treatment Tyvaso DPI to...